Reuters: Health
German biotech company Morphosys' tafasitamab, the group's most advanced drug which is currently being tested, has sales potential of significantly more than $1 billion a year, its finance chief said in remarks to a magazine.
Morphosys CFO says tafasitamab drug sales potential above $1 billion: magazine
Morphosys CFO says tafasitamab drug sales potential above $1 billion: magazine
Reuters: Health
German biotech company Morphosys' tafasitamab, the group's most advanced drug which is currently being tested, has sales potential of significantly more than $1 billion a year, its finance chief said in remarks to a magazine.
Reuters: Health
German biotech company Morphosys' tafasitamab, the group's most advanced drug which is currently being tested, has sales potential of significantly more than $1 billion a year, its finance chief said in remarks to a magazine.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment